Compugen (NASDAQ:CGEN) Stock Passes Above Two Hundred Day Moving Average – Time to Sell?

Compugen Ltd. (NASDAQ:CGEN)’s share price crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $2.21 and traded as high as $2.38. Compugen shares last traded at $2.37, with a volume of 154,774 shares changing hands.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on CGEN shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Compugen in a research note on Monday, April 20th. Wall Street Zen lowered shares of Compugen from a “buy” rating to a “hold” rating in a research note on Saturday, May 23rd. Lake Street Capital assumed coverage on shares of Compugen in a report on Tuesday, April 7th. They issued a “buy” rating and a $6.00 price objective for the company. Leerink Partners cut their target price on shares of Compugen from $13.00 to $5.00 and set an “outperform” rating on the stock in a research note on Thursday, May 21st. Finally, Truist Financial upgraded shares of Compugen to a “strong-buy” rating in a report on Wednesday, March 25th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $5.00.

Compugen Stock Performance

The company has a 50 day moving average of $2.36 and a 200 day moving average of $2.21. The stock has a market capitalization of $224.09 million, a price-to-earnings ratio of 6.41 and a beta of 2.76.

Compugen (NASDAQ:CGEN) last posted its quarterly earnings results on Monday, May 18th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.01). The company had revenue of $2.18 million during the quarter, compared to analyst estimates of $1.57 million. Compugen had a net margin of 47.97% and a return on equity of 47.72%. As a group, research analysts expect that Compugen Ltd. will post -0.28 EPS for the current fiscal year.

Institutional Trading of Compugen

Several hedge funds have recently added to or reduced their stakes in CGEN. Bank Hapoalim BM acquired a new position in Compugen during the 4th quarter worth approximately $37,000. Security National Bank of Sioux City Iowa IA acquired a new stake in shares of Compugen in the 4th quarter valued at $38,000. Calamos Advisors LLC purchased a new stake in shares of Compugen during the 1st quarter worth $63,000. Franklin Resources Inc. acquired a new position in shares of Compugen during the second quarter worth $56,000. Finally, Hillsdale Investment Management Inc. acquired a new position in shares of Compugen during the first quarter worth $68,000. Institutional investors and hedge funds own 12.22% of the company’s stock.

About Compugen

Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.

Compugen’s predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.